MKC253 is a formulation of GLP-1 (glucagon-like peptide) on Technosphere® particles that is delivered using our proprietary inhaler.
In initial clinical studies, MKC253 has shown a robust enhancement of insulin secretion without gastrointestinal (GI) intolerance. Our hypothesis at present is that delivery of active GLP-1 to the arterial circulation, via the lung, avoids significant degradation by dipeptidyl peptidase-4 that occurs prior to the compound reaching the primary site of endocrine action. Thus, it may be possible to achieve a different response profile with pulmonary MCK253 than seen with subcutaneous or intravenous administration of GLP-1. Moreover, the pulsatile administration of MKC253 achieved with the Technosphere® delivery technology appears to avoid the dose-limiting GI intolerance characteristically associated with GLP-1 and replaces the insulin response lost in patients with diabetes that cannot be replicated by other forms of GLP-1.
We believe that MKC253 represents a novel approach to the use of GLP-1 as a prandial therapy for diabetes, either alone or in combination with prandial insulin.